Details

Autor(en) / Beteiligte

• Gao, Fei
• Jiang, Yifeng
• Li, Guoxin
• Zhou, Yanjun
• Yu, Lingxue
• Li, Liwei
• Tong, Wu
• Zheng, Hao
• Zhang, Yujiao
• Yu, Hai
• Shan, Tongling
• Yang, Shen
• Liu, Huan
• Zhao, Kuan
• Tong, Guangzhi

Titel

Porcine reproductive and respiratory syndrome virus expressing E2 of classical swine fever virus protects pigs from a lethal challenge of highly-pathogenic PRRSV and CSFV

Ist Teil von

• Vaccine, 2018-05, Vol.36 (23), p.3269-3277

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2018

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •The CSFV E2 gene was expressed as a unique sg mRNA in PRRSV genome.•rPRRSV-E2 could be stable for at least 25 cell passages.•The immune response of rPRRSV-E2 was similar to that of HuN4-F112.•rPRRSV-E2 is promising as a virus-vectored vaccine against both PRRSV and CSFV infection in swine herds by single vaccination. Porcine reproductive and respiratory syndrome (PRRS) and classical swine fever (CSF) are economically significant diseases that affect the swine industry worldwide. However, the current vaccination strategy, which uses two single live attenuated vaccines, can result in interference for each other. In addition, the universally used CSFV vaccine C-strain does not allow for differentiation of infected and vaccinated animals. In this study, rPRRSV-E2, PRRS virus (PRRSV) expressing CSF virus (CSFV) E2, was constructed by reverse genetics. The E2 gene of CSFV was inserted between ORF1b and ORF2 in the genome of the PRRS vaccine virus, HuN4-F112. A copy of transcriptional regulatory sequence 6 was inserted at the 3′ terminal of the exogenous gene to produce CSFV E2 as a unique subgenomic mRNA transcript. The rPRRSV-E2 was stable for at least 25 serial cell passages. Single-shot intramuscular immunization of rPRRSV-E2 into pigs induced PRRSV-specific and CSFV-specific antibodies and fully protected pigs from lethal challenge with highly-pathogenic PRRSV and CSFV. These results demonstrate that a novel strategy for recombinant PRRSV production is effective, and suggest that rPRRSV-E2 is a promising live, virus-vectored vaccine against PRRS and a marker vaccine against CSF.